ReviewDiagnostics (Basel, Switzerland)2022
The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07286526 (Comparison of Bolus and Continuous Hydration Regimens for the Prevention of Contrast-Associated Acute Kidney Injury in the Emergency Department), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Bolus and Continuous Hydration Regimens for the Prevention of Contrast-Associated Acute Kidney Injury in the Emergency Department: A Randomized Controlled Non-Inferiority Trial
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pooled it
- The Role of Cystatin C in the Prediction of Contrast-Induced Acute Kidney Injury Following Coronary Procedures: A Systematic Review.Reviews in cardiovascular medicine · 2025Pooled it
- Impact of SGLT2 Inhibitors on Renal Function in Type 2 Diabetic Patients with Coronary Artery Disease Undergoing Percutaneous Intervention: A Systematic Review and Meta-Analysis.Current diabetes reviews · 2025Pooled it
- Pooled it
- Preventing Contrast-Induced Acute Kidney Injury in Egyptian Patients Undergoing Coronary Angiography: A Randomized Controlled Trial.Clinical drug investigation · 2026Trial
- Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.Renal failure · 2023Trial
- Disasters and crush syndrome-related acute kidney injury: What pediatric nephrologists should know.Pediatric nephrology (Berlin, Germany) · 2026Review
- Protective effects of dexpanthenol against diatrizoate-induced contrast nephropathy via the SIRT1-p53-Bcl-2/Bax pathway in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Contrast-induced acute kidney injury and nephrogenic systemic fibrosis in children.Pediatric nephrology (Berlin, Germany) · 2026Review
- US Food and Drug Administration black box warnings: Characteristics of drug classes and adverse effects.The Journal of pharmacology and experimental therapeutics · 2026Article
- Comparison of Bolus and Continuous Hydration Regimens for the Prevention of Contrast-Associated Acute Kidney Injury in the Emergency Department: A Randomized Controlled Noninferiority Trial.Emergency medicine international · 2026Article
- It is not only fluids: the impact of hydration protocols used for the prevention of contrast nephropathy on renal oxygenation.Renal failure · 2025Review
- Comparative Evaluation of Clinical and Immunonutritional Risk Scores for Predicting Contrast-Associated Acute Kidney Injury in Emergency Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Efficacy of Coronary Sinus Aspiration in Reducing Contrast-Induced Nephropathy in High-Risk Patients.JACC. Advances · 2025Article
- Article
- The Incidence of Contrast-Induced Nephropathy Following Computed Tomography and Associated Risk Factors.Radiology research and practice · 2025Article
- Reduction in the risk of contrast-induced nephropathy using enhanced external counter-pulsation in patients with chronic kidney disease.Renal failure · 2024Article
- [Biomarkers of oxidative stress and inflammation in contrast-associated acute kidney injury].Anales del sistema sanitario de Navarra · 2024Article
- High-mobility group box 1 and its related receptors: potential therapeutic targets for contrast-induced acute kidney injury.International urology and nephrology · 2024Review
- Navigating nephrotoxic waters: A comprehensive overview of contrast-induced acute kidney injury prevention.World journal of radiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast-induced nephropathy (CIN) is an impairment of renal function that occurs after the administration of an iodinated contrast medium (CM). Kidney dysfunction in CIN is considered transient and reversible in most cases. However, it is the third most common cause of hospital-acquired acute kidney injury and is associated with increased morbidity and mortality, especially in high-risk patients. Diagnostic and interventional procedures that require intravascular CM are being used with increasing frequency, especially among the elderly, who can be particularly susceptible to CIN due to multiple comorbidities. Therefore, identifying the exact mechanisms of CIN and its associated risk factors is crucial not only to provide optimal preventive management for at-risk patients, but also to increase the feasibility of diagnostic and interventional procedure that use CM. CM induces kidney injury by impairing renal hemodynamics and increasing the generation of reactive oxygen species, in addition to direct cytotoxicity. Periprocedural hydration is the most widely accepted preventive strategy to date. Here, we review the latest research results on the pathophysiology and management of CIN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.